Premium
Cost‐Benefit Analysis of Cholinesterase Inhibitors (ChEI) in Alzheimer's Disease (AD)
Author(s) -
Lanctôt K.L.,
Oh P.I.,
Risebrough N.,
Herrmann N.
Publication year - 1999
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/s0009-9236(99)80209-4
Subject(s) - cholinesterase , pharmacology , clinical pharmacology , medicine , galantamine , tacrine , alzheimer's disease , disease , donepezil , dementia , acetylcholinesterase , biology , enzyme , biochemistry
Clinical Pharmacology & Therapeutics (1999) 65 , 169–169; doi: